{Reference Type}: English Abstract
{Title}: [Study on the Regulation of Chidamide on CD8+T Cells in T-cell Acute Lymphoblastic Leukemia].
{Author}: Yan MM;Li ZX;Chen C;Zhang W;Zhou DB;
{Journal}: Zhongguo Shi Yan Xue Ye Xue Za Zhi
{Volume}: 31
{Issue}: 1
{Year}: Feb 2023
暂无{DOI}: 10.19746/j.cnki.issn.1009-2137.2023.01.011
{Abstract}: OBJECTIVE: To explore the regulatory effect of chidamide on CD8+ T cells in T-cell acute lymphoblastic leukemia.
METHODS: The expression levels of CXCL9 and CXCL3 mRNA in Jurkat cells, lymphocytes treated with chidamide and lymphocytes co-cultured with chidamide-treated Jurkat cells were detected by fluorescence quantitative PCR. The proportion of CD8+ T cells in lymphocytes treated with chidamide and lymphocytes co-cultured with chidamide-treated Jurkat cells was determined by flow cytometry.
RESULTS: Chidamide upregulated CXCL9 mRNA expression in Jurkat cell line in a dose-dependent manner (r=0.950). The mRNA expression of CXCL9 in chidamide 5 μmol/L group was 164 times higher than that in control group. Chidamide upregulated CXCL9 mRNA expression in lymphocytes, but the up-regulated level was significantly lower than that in Jurkat cell line treated with the same concentration of chidamide. Co-culture with chidamide treated Jurkat cells upregulated the proportion of CD8+ T cells in lymphocytes.
CONCLUSIONS: In T-cell acute lymphoblastic leukemia, chidamide may increase the concentration of CXCL9 in the tumor microenvironment by up-regulating the expression of CXCL9 in tumor cells, leading to an increase in the number of CD8+ T cells.
UNASSIGNED: 西达本胺对急性T淋巴细胞白血病CD8+ T细胞的 调控作用研究.
UNASSIGNED: 探讨西达本胺对急性T淋巴细胞白血病CD8+T细胞的调控作用.
UNASSIGNED: 通过荧光定量PCR检测西达本胺处理的Jurkat细胞、淋巴细胞、与西达本胺处理的Jurkat细胞共培养的淋巴细胞的CXCL9、CXCL3 mRNA表达水平。通过流式细胞术检测西达本胺处理的淋巴细胞、与西达本胺处理的Jurkat细胞共培养的淋巴细胞中CD8+T细胞的比 例.
UNASSIGNED: 西达本胺上调Jurkat细胞系CXCL9的mRNA表达，上调水平呈剂量依赖（r=0.950），西达本胺5 μmol/L 组的CXCL9 mRNA表达是无处理组的164倍。西达本胺上调淋巴细胞CXCL9的mRNA表达，上调水平明显低于同浓度西达本胺处理的Jurkat细胞系。与西达本胺处理的Jurkat细胞共培养，可以上调淋巴细胞中CD8+T细胞的比例.
UNASSIGNED: 急性T淋巴细胞白血病中，西达本胺可能通过上调肿瘤细胞CXCL9的表达，增加肿瘤微环境中CXCL9的浓度，导致CD8+T细胞数量的增加.